Deutetrabenazine

Drug Profile

Deutetrabenazine

Alternative Names: Austedo; d6-tetrabenazine; Deuterium-substituted tetrabenazine; Dutetrabenazine; SD-809; SD-809 ER; SD-809 Extended Release

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Auspex Pharmaceuticals; Teva Pharmaceutical Industries
  • Class Antipsychotics; Neuroprotectants; Organic deuterium compounds; Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Dopamine release inhibitors; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome; Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • Registered Chorea
  • Preregistration Drug-induced dyskinesia
  • No development reported Gilles de la Tourette's syndrome

Most Recent Events

  • 03 Apr 2017 Registered for Chorea in USA (PO, tablet) first-global approval
  • 03 Apr 2017 The approved label for Deutetrabenazine has a black box warning
  • 28 Feb 2017 Preregistration for Drug-induced dyskinesia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top